Our clinical pipeline aims to develop formulations of deucrictibant, an oral B2 receptor antagonist, for both acute treatment and prevention of HAE. Learn more.

Careers Investors & Media Contact SCIENCE PIPELINE DISEASE FOCUS HAE COMMUNITY CLINICAL TRIALS ABOUT US

Deucrictibant is an oral molecule with the potential to address both the on-demand & prophylactic treatment modalities for people living with HAE. Learn more.

Find the latest news and updates on Pharvaris, a biopharmaceutical company focused on bradykinin-mediated diseases.

Multiple conditions, including HAE, can result in excess bradykinin. Blocking bradykinin shuts down the swelling attack caused by these diseases. Learn more.

Recent Business Updates and Highlights Development Pipeline Enrollment initiated in RAPIDe-3 (NCT06343779) a global Phase 3 clinical study. Pharvaris is currently enrolling in RAPIDe-3, a global …

Recent Pipeline and Business Highlights and Upcoming Milestones Pipeline • Phase 2 on-demand study (RAPIDe-1) of PHVS416 proceeding toward data readout in 2022. In February 2021, Pharvaris …

Careers Investors & Media Contact SCIENCE PIPELINE DISEASE FOCUS HAE COMMUNITY CLINICAL TRIALS ABOUT US

We plan to evaluate prophylactic treatment of HAE by initiating two studies in 2021: a second Phase 2 study of PHVS416 and a Phase 1 study of PHVS719, our extended-release product candidate. …

Pharvaris is developing therapies for people living with HAE, a rare and potentially life-threatening genetic disease, and other bradykinin-mediated diseases.